Immune · Investigational
Imuthiol (Diethyldithiocarbamate)
No lawful US pathway
01 · Overview
Imuthiol (ditiocarb sodium) is the sodium salt of diethyldithiocarbamate, a small sulfur-containing molecule rather than a peptide, which was explored as an immunomodulator in the late 1980s and early 1990s. Its proposed mechanisms included modulation of T-cell function and metal-chelating antioxidant activity.
Therapeutic interest focused on slowing disease progression in HIV infection.
02 · Research summary & key findings
Early randomized, placebo-controlled trials in HIV infection reported fewer progressions to AIDS and improved CD4 counts (PMID 2901566), delayed disease progression with intravenous treatment (PMID 1969060), and fewer new opportunistic infections in symptomatic patients (PMID 1671884). However, a large multicenter trial of 1,333 asymptomatic or minimally symptomatic patients found a significantly higher risk of progression to AIDS with ditiocarb than placebo and recommended that its use be discontinued (PMID 8094001). It was never approved and is no longer in development for HIV.
03 · Regulatory status
Imuthiol (Diethyldithiocarbamate) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Imuthiol (Diethyldithiocarbamate) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding.
See the 1 FDA-approved compound in Immune
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
04 · Administration routes
- Intravenous
- Oral
References
- [1]Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study JAMA, 1991. PMID 1671884
- [2]Inhibition of HIV progression by dithiocarb. German DTC Study Group Lancet, 1990. PMID 1969060
- [3]Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('Imuthiol') in human immunodeficiency virus infection Lancet, 1988. PMID 2901566
- [4]Multicenter, randomized, placebo-controlled study of ditiocarb (Imuthiol) in human immunodeficiency virus-infected asymptomatic and minimally symptomatic patients. The HIV87 Study Group AIDS Res Hum Retroviruses, 1993. PMID 8094001
Primary literature
- PubMed: "Imuthiol"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Imuthiol"
Registered interventional and observational studies, including status and phase.
- PubChem: "Imuthiol"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Immune
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.